Nippon India Pharma Fund-Growth
The fund is rated 0 stars. Balance between returns and downside risk provided limited support. Investment selection within each asset type and investment selection within each industry were the main limitations and did not provide enough support for a higher rating. Higher annual fee of 1.84% and above-average fund size of Rs 9,479.08 crore were minor drawbacks.
This fund has a bad track record with Asset Selection/Timing, a bad track record with Stock Selection/Timing. It is important to note, however, that this fund has a 9479.076 AUM and a 1.84 expense ratio. Considering all these factors, we have rated this fund as 0.0 star.
आमचा स्कोअर दीर्घकालीन कामगिरी, जोखीम आणि सातत्य यांचे वजन करतो — फक्त मागील परतावे नाही.
परतावा
8 Oct 2026 पर्यंत
जोखीम गुणोत्तरे
30 Sep 2026 पर्यंत
पोर्टफोलिओ
31 Aug 2026 पर्यंत
मार्केट-कॅप विभागणी
क्षेत्रनिहाय वाटप
होल्डिंग्स (37)
| होल्डिंग | फंडाचा % | मूल्य | शेअर्स |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 12.37% | ₹1,172.29 Cr | 59,06,349 |
| Divi's Laboratories Ltd. | 7.00% | ₹663.4 Cr | 7,00,754 |
| Lupin Ltd. | 6.43% | ₹609.25 Cr | 27,83,991 |
| Cipla Ltd. | 6.09% | ₹577.08 Cr | 40,95,054 |
| Apollo Hospitals Enterprise Ltd. | 5.15% | ₹488.35 Cr | 5,48,795 |
| Dr. Reddy's Laboratories Ltd. | 4.93% | ₹467.5 Cr | 40,49,746 |
| Mankind Pharma Ltd. | 4.09% | ₹387.93 Cr | 16,03,562 |
| Sai Life Sciences Ltd. | 3.94% | ₹373.06 Cr | 25,55,745 |
| Ajanta Pharma Ltd. | 3.47% | ₹329.18 Cr | 9,13,918 |
| Glaxosmithkline Pharmaceuticals Ltd. | 3.31% | ₹314 Cr | 10,29,460 |
फंड तपशील
Long term capital growth. Investment in equity and equity related Securities of pharma & other associated companies.
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Exit load of 1% if redeemed within 1 month.